Roche Drug ‘Significantly’ Extended Lives in Cancer Trial

Roche Holding AG’s experimental breast cancer drug T-DM1 “significantly” extended the lives of breast cancer patients in a trial that may improve the likelihood of approval of the medicine.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.